



BioXcel Therapeutics Announces Presentation on Functional Immunological Memory Formation Across Diverse Tumor Types at the SITC 2018 Annual Meeting

October 31, 2018

Data underscores the potential of triple combination of BXCL701, NKTR-214 and an anti-PD1 agent as an anti-cancer therapy

NEW HAVEN, Conn., Oct. 31, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI") (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that the Company will present data on the combination of BTI's BXCL701, Nektar Therapeutics' NKTR-214 and an anti-PD1 across multiple tumor types at the upcoming Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting from November 7-11, 2018 in Washington, D.C.

Details of the poster are below:

Abstract #P368:	Combination of a dipeptidyl peptidase inhibitor BXCL701 and biased CD122 agonist NKTR-214 with anti-PD1 provides functional immunological memory through inflammatory cell death
Date and Time:	Friday, November 9 th , 8 a.m. – 8 p.m. ET; Saturday, November 10 th , 8 a.m. – 8:30 p.m. ET
Session:	Combination Therapy
Presenting Author:	John MacDougall

About BioXcel Therapeutics, Inc.:

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. The Company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The Company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit www.bioxccltherapeutics.com.

Contact Information:

The Ruth Group
Lee Roth/ Janhavi Mohite
646-536-7012/ 7026
lroth@theruthgroup.com/ jmohite@theruthgroup.com

Source: BioXcel Therapeutics, Inc.